Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

AGEN

Agenus Inc

Jan 24 • 02:40PM ET

3.63

Dollar change -0.13
Percentage change -3.46	%

Healthcare • Biotechnology • USA • NASD

Peers: BMY MRK PFE GILD JNJ AMGN VRTX REGN BIIB LLY

| Held by: IWM VTI VXF IWN VTWO IWO FESM IWC VHT CNCR

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-11.00	Insider Own	4.70%	Shs Outstand	23.46M	Perf Week	15.24%
Market Cap	85.16M	Forward P/E	-	EPS next Y	-8.91	Insider Trans	0.00%	Shs Float	22.36M	Perf Month	28.27%
Income	-227.86M	PEG	-	EPS next Q	-2.64	Inst Own	33.68%	Short Float	13.21%	Perf Quarter	-19.15%
Sales	160.43M	P/S	0.53	EPS this Y	11.83%	Inst Trans	-4.02%	Short Ratio	5.59	Perf Half Y	-40.78%
Book/sh	-13.48	P/B	-	EPS next Y	26.76%	ROA	-79.32%	Short Interest	2.95M	Perf Year	-69.64%
Cash/sh	1.91	P/C	1.90	EPS next 5Y	-	ROE	-	52W Range	2.50 - 19.69	Perf YTD	32.48%
Dividend Est.	-	P/FCF	-	EPS past 5Y	13.79%	ROI	-	52W High	-81.56%	Beta	1.33
Dividend TTM	-	Quick Ratio	0.19	Sales past 5Y	46.68%	Gross Margin	90.08%	52W Low	45.20%	ATR (14)	0.31
Dividend Ex-Date	-	Current Ratio	0.19	EPS Y/Y TTM	32.67%	Oper. Margin	-62.83%	RSI (14)	58.25	Volatility	10.75% 8.96%
Employees	389	Debt/Eq	-	Sales Y/Y TTM	59.00%	Profit Margin	-142.03%	Recom	2.60	Target Price	7.75
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	6.36%	Payout	-	Rel Volume	0.62	Prev Close	3.76
Sales Surprise	-24.99%	EPS Surprise	-33.12%	Sales Q/Q	3.28%	Earnings	Nov 12 BMO	Avg Volume	528.41K	Price	3.63
SMA20	12.64%	SMA50	14.63%	SMA200	-50.47%	Trades		Volume	263,040	Change	-3.46%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-19-24	Downgrade	Robert W. Baird	Outperform → Neutral	$35 → $8
Jul-18-24	Downgrade	William Blair	Outperform → Mkt Perform
Jul-18-24	Downgrade	H.C. Wainwright	Buy → Neutral	$9
Jun-06-23	Initiated	Robert W. Baird	Outperform	$8
Jun-06-23	Initiated	Robert W. Baird	Outperform	$60 → $80
Feb-28-23	Resumed	H.C. Wainwright	Buy	$8
Sep-28-22	Initiated	SMBC Nikko	Outperform	$5
Dec-16-21	Initiated	H.C. Wainwright	Buy	$12
Nov-19-19	Resumed	B. Riley FBR	Buy	$6
Apr-22-19	Initiated	B. Riley FBR	Buy
Oct-28-16	Downgrade	H.C. Wainwright	Buy → Neutral	$10 → $5
Oct-27-16	Reiterated	Maxim Group	Buy
Mar-11-16	Upgrade	Maxim Group	Hold → Buy	$7
Dec-16-15	Initiated	Jefferies	Buy
Oct-27-15	Downgrade	Maxim Group	Buy → Hold
Jul-27-15	Reiterated	MLV & Co	Buy	$9 → $11
Jun-11-15	Initiated	Oppenheimer	Outperform	$14
Jan-12-15	Reiterated	Maxim Group	Buy	$10 → $11
Jan-09-15	Reiterated	MLV & Co	Buy	$6 → $9
Jan-09-15	Reiterated	Maxim Group	Buy	$10 → $11

Show Previous Ratings

Jan-22-25 02:48PM	Agenus Presents Data at ASCO GI Demonstrating Impact of BOT/BAL in Colorectal Cancer Across Neoadjuvant and Advanced Disease (Business Wire)
Jan-20-25 12:00PM	What Makes Agenus (AGEN) a New Buy Stock (Zacks)
09:40AM	Is Agenus (AGEN) Stock Outpacing Its Medical Peers This Year? (Zacks)
Dec-18-24 07:30AM	Agenus Announces Five Presentations at ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric Cancers (Business Wire) -8.12%
Dec-06-24 06:07AM	AstraZeneca, Daiichi build cancer drug case; Amgen invests $1B (BioPharma Dive) +14.01%
07:30AM	Loading…
Dec-05-24 07:30AM	Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs (Business Wire) -8.45%
Nov-27-24 10:20AM	Agenus Gets $22M Mortgage, Plans Strategic Realignment To Focus On Colorectal Cancer Drug Development (Benzinga)
08:15AM	Agenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment (Business Wire)
Nov-19-24 09:35AM	Agenus (AGEN) Loses -41.56% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Nov-18-24 09:35AM	Agenus (AGEN) Loses -41.13% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Nov-15-24 09:35AM	Down -39.39% in 4 Weeks, Here's Why Agenus (AGEN) Looks Ripe for a Turnaround (Zacks)
Nov-13-24 02:18AM	Q3 2024 Agenus Inc Earnings Call (Thomson Reuters StreetEvents)
02:08AM	Agenus Inc (AGEN) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges While ... (GuruFocus.com)
Nov-12-24 12:15PM	Agenus (AGEN) Q3 2024 Earnings Call Transcript (Motley Fool) -20.38%
08:20AM	Agenus (AGEN) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:19AM	Loading…
07:19AM	Agenus: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Agenus Reports Third Quarter 2024 Financial Results and Strategic Advancements in BOT/BAL Development (Business Wire)
Nov-11-24 07:24AM	Earnings To Watch: Agenus Inc (AGEN) Reports Q3 2024 Result (GuruFocus.com)
Nov-07-24 10:00AM	Agenus to Present Compelling Data on Botensilimab and AGEN1721 at SITC 2024 (Business Wire) -6.87%
07:00AM	Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance (Business Wire)
Nov-05-24 07:30AM	Agenus to Provide Third Quarter 2024 Financial Report and Corporate Update (Business Wire)
Nov-01-24 05:45AM	Investors in Agenus Inc. Should Contact Levi & Korsinsky Before November 5, 2024 to Discuss Your Rights - AGEN (PR Newswire)
Oct-29-24 05:45AM	Investors in Agenus Inc. Should Contact Levi & Korsinsky Before November 5, 2024 to Discuss Your Rights - AGEN (PR Newswire)
Sep-19-24 01:31PM	Agenus Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before November 5, 2024 to Discuss Your Rights AGEN (GlobeNewswire)
Sep-17-24 05:45AM	Agenus Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before November 5, 2024 to Discuss Your Rights - AGEN (PR Newswire)
Sep-16-24 12:51PM	Agenus Inc. Sued for Securities Law Violations Investors Should Contact Levi & Korsinsky Before November 5, 2024 to Discuss Your Rights AGEN (GlobeNewswire)
Sep-13-24 10:00AM	Botensilimab/Balstilimab Clinical Responses in Refractory Sarcomas Presented at ESMO 2024 (Business Wire) +5.56%
Sep-09-24 07:30AM	Botensilimab/Balstilimab Clinical Activity in Refractory Sarcomas to be Presented in Oral Session at ESMO 2024 (Business Wire)
Sep-03-24 07:30AM	Agenus to Participate in September Investor Conferences (Business Wire)
Aug-08-24 04:15PM	Agenus (AGEN) Q2 2024 Earnings Call Transcript (Motley Fool)
08:10AM	Loading…
08:10AM	Agenus (AGEN) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:08AM	Agenus: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Agenus Reports Second Quarter 2024 Operational and Financial Results (Business Wire)
07:00AM	Agenus Announces Appointment of Tom Harrison to Board of Directors (Business Wire)
Aug-07-24 10:58AM	Agenus Publishes Seminal Study on Botensilimabs Activity in Treatment-Resistant Cancers (Business Wire) -6.45%
Aug-05-24 02:31PM	Bristol Myers Squibb Terminates Cancer Drug Development Program With Agenus (Benzinga) -6.93%
07:23AM	Bristol Myers sends TIGIT drug back to Agenus (BioPharma Dive)
Aug-01-24 10:01AM	Agenus (AGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jul-26-24 07:00AM	Agenus to Provide Second Quarter 2024 Financial Report and Corporate Update (Business Wire) +9.97%
Jul-19-24 10:39AM	Agenus (AGEN) Tanks on Colorectal Cancer Study Interim Data (Zacks) -17.95%
07:47AM	Lilly alone in bidding for Morphic; Novartis wont yet file MorphoSys drug (BioPharma Dive)
Jul-18-24 07:00AM	Agenus Announces End-of-Phase-2 Meeting Outcomes and Topline Interim Phase 2 Data for BOT/BAL in MSS Colorectal Cancer (Business Wire) -58.83%
Jun-28-24 11:10AM	Significant Tumor Reductions in Neoadjuvant MSS Colon Cancer Patients Treated with Botensilimab/Balstilimab Presented at ESMO GI Conference (Business Wire) +18.63%
Jun-27-24 07:30AM	Cancer Therapy Evaluation Program Announces Availability of Botensilimab for Clinical Studies (Business Wire)
Jun-17-24 07:00AM	Agenus Announces Appointment of Dr. Jennifer Buell to Its Board of Directors (Business Wire) -7.50%
Jun-13-24 05:15AM	Nature Medicine Reports Agenus Novel Immunotherapy Demonstrates Clinical Activity Against a Deadly Form of Colorectal Cancer on the Rise in Americans Under 50 (Business Wire) -5.44%
Jun-04-24 07:30AM	Agenus Announces Virtual Annual Shareholders Meeting (Business Wire)
May-30-24 03:30PM	Medical Moonshots: 3 Biotech Stocks Set to Skyrocket (InvestorPlace)
May-27-24 12:32PM	7 Biotech Stocks to Put on Your Breakthrough Radar (InvestorPlace)
May-24-24 05:00PM	Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +10.28% +11.97%
May-23-24 05:10PM	Breakthrough Data on Botensilimab/Balstilimab in MSS CRC Presented at the 2024 ASCO Annual Meeting (Business Wire)
07:30AM	Agenus to Participate in Goldman Sachs 45th Annual Global Healthcare Conference (Business Wire)
May-22-24 07:30AM	3 Magnificent Growth Stocks to Buy Hand Over Fist (Motley Fool) +7.10%
May-16-24 07:30AM	FDA Grants Agenus Type B End-of-Phase 2 Meeting to Discuss BOT/BAL Therapy for Relapsed or Refractory Metastatic Colorectal Cancer (Business Wire)
May-08-24 01:22PM	Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2024 Earnings Call Transcript (Insider Monkey)
11:11AM	Agenus Inc. (NASDAQ:AGEN) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:09AM	Agenus Inc (AGEN) Q1 2024 Earnings Call Transcript Highlights: Strategic Developments and ... (GuruFocus.com)
May-07-24 05:45PM	Agenus (AGEN) Q1 2024 Earnings Call Transcript (Motley Fool) -7.26%
01:52PM	Sector Update: Health Care Stocks Stronger in Tuesday Afternoon Trading (MT Newswires)
12:24PM	Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates (MT Newswires)
09:00AM	Agenus (AGEN) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
08:56AM	Agenus Inc (AGEN) Q1 2024 Earnings: Misses Revenue and EPS Estimates Amid Strategic Developments (GuruFocus.com)
07:59AM	Agenus: Q1 Earnings Snapshot (Associated Press Finance)
07:40AM	Agenus Reports First Quarter 2024 Results (Business Wire)
07:30AM	Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement (Business Wire)
May-01-24 07:30AM	Agenus Regains Compliance with Nasdaq Minimum Bid Price Requirement (Business Wire) +9.41%
Apr-28-24 08:30AM	Up 40%: Is This Red-Hot Growth Stock Still a Buy? (Motley Fool)
Apr-24-24 10:00AM	Botensilimab/Balstilimab Data in MSS CRC Selected for the American Society of Clinical Oncology 2024 Annual Meeting (Business Wire) +14.86%
Apr-23-24 07:30AM	Agenus to Provide First Quarter 2024 Financial Report and Corporate Update (Business Wire) +11.96%
Apr-22-24 04:17AM	Agenus (AGEN) Soars 6.8%: Is Further Upside Left in the Stock? (Zacks) +8.66%
Apr-12-24 07:30AM	Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer (Business Wire) -8.12%
Apr-08-24 03:34AM	Down 75%. Is Agenus Stock a Buy on the Dip? (Motley Fool) -7.58%
Apr-05-24 04:30PM	Agenus Announces Reverse Stock Split of Common Stock (Business Wire)
Apr-03-24 04:19AM	2 Stocks That Could More Than Double Your Money, According to Wall Street: Are They Buys Now? (Motley Fool)
Mar-24-24 04:05PM	3 Mind-Blowing Stocks That Could Turn $1,000 Into $1 Million (InvestorPlace)
Mar-22-24 01:25PM	MiNK Therapeutics, Inc. (NASDAQ:INKT) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-15-24 02:11PM	Agenus Inc. (NASDAQ:AGEN) Q4 2023 Earnings Call Transcript (Insider Monkey) -9.95%
Mar-14-24 01:30PM	Agenus (AGEN) Q4 2023 Earnings Call Transcript (Motley Fool) -8.94%
08:51AM	Agenus Inc (AGEN) Reports Full Year and Q4 2023 Financial Results, Advances in Oncology Pipeline (GuruFocus.com)
07:39AM	Agenus: Q4 Earnings Snapshot (Associated Press Finance)
07:30AM	Agenus Reports Fourth Quarter and Full Year 2023 Results (Business Wire)
Mar-06-24 07:30AM	Agenus Announces Preclinical Data on BMS-986442 (AGEN1777) at AACR 2024 (Business Wire)
Mar-05-24 04:30PM	Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-29-24 07:30AM	Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report (Business Wire) -10.81%
Feb-26-24 07:30AM	Agenus to Participate in Leerink Partners Global Biopharma Conference (Business Wire) +6.36%
Feb-15-24 06:38PM	Why Agenus Stock Plummeted by Nearly 30% on Its Stock Split News Today (Motley Fool) -29.54%
07:02AM	Ginkgo Bioworks and SaponiQx Awarded MCDC Contract to Discover and Manufacture Next-Generation Vaccine Adjuvants Using Generative Molecular Design (PR Newswire)
Feb-01-24 07:09PM	7 Analyst-Backed Stocks With Promising 10-Bagger Potential (InvestorPlace)
Jan-31-24 07:30AM	Agenus to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference (Business Wire) +5.32%
Jan-26-24 03:57PM	3 Biotech Stocks with Potential for Major Medical Breakthroughs in 2024 (InvestorPlace) +10.47%
Jan-22-24 07:30AM	Botensilimab/Balstilimab Breakthrough Data Presented at ASCO-GI Shows Unprecedented Tumor Shrinkage and Robust Biomarker Response in Prevalent Colorectal Cancer Population (Business Wire)
Jan-05-24 04:30PM	Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-04-24 07:30AM	Agenus to Participate in B. Riley Healthcare Conference (Business Wire)
Dec-24-23 09:45AM	2 Small Cap Stocks That Could Go Parabolic in 2024, According to Wall Street (Motley Fool)
Dec-20-23 07:30AM	Botensilimab/Balstilimab Data in Neoadjuvant Colorectal Cancer Selected for ASCO-GI 2024 (Business Wire)
Dec-11-23 07:30AM	Agenus to Receive $25 Million Milestone Payment from Bristol Myers Squibb for TIGIT-CD96 Bispecific Program (Business Wire) -8.91%
Nov-07-23 06:55AM	Agenus Inc (AGEN) Reports Q3 2023 Results: Revenue of $24.3 Million and Net Loss of $64.5 Million (GuruFocus.com)
06:41AM	Agenus: Q3 Earnings Snapshot (Associated Press Finance)
06:30AM	Agenus Reports Third Quarter 2023 Results (Business Wire)
Oct-26-23 09:05AM	Agenus to Provide Third Quarter 2023 Financial Report and Corporate Update (Business Wire)

Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ARMEN GARO H	See Remarks	Feb 15 '24	Buy	0.65	500,000	324,050	625,969	Feb 15 06:59 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AGEN

Agenus Inc

Upgrade your FINVIZ experience